|
๐
|
Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials
24 auth.
P. Sax,
D. Wohl,
M. Yin,
F. Post,
E. Dejesus,
M. Saag,
A. Pozniak,
M. Thompson,
D. Podzamczer,
J. Molina,
...
S. Oka,
E. Koenig,
B. Trottier,
J. Andrade-Villanueva,
G. Crofoot,
J. Custodio,
Andrew Plummer,
Lijie Zhong,
H. Cao,
Hal Martin,
C. Callebaut,
A. Cheng,
M. Fordyce,
S. McCallister
|
9 |
2015 |
9
๐
|
|
๐ฌ
|
Tenofovir alafenamide: A novel prodrug of tenofovir for the treatment of Human Immunodeficiency Virus.
A. Ray,
M. Fordyce,
M. Hitchcock
|
8 |
2016 |
8
๐ฌ
|
|
๐ข
|
Current status and prospects of HIV treatment.
T. Cihlรกล,
M. Fordyce
|
8 |
2016 |
8
๐ข
|
|
๐
|
Tenofovir Alafenamide Vs. Tenofovir Disoproxil Fumarate in Single Tablet Regimens for Initial HIV-1 Therapy: A Randomized Phase 2 Study
11 auth.
P. Sax,
A. Zolopa,
I. Brar,
R. Elion,
Roberto Ortiz,
F. Post,
...
Hui Wang,
C. Callebaut,
Hal Martin,
M. Fordyce,
S. McCallister
|
7 |
2014 |
7
๐
|
|
๐ข
|
Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study
19 auth.
A. Pozniak,
J. Arribas,
J. Gathe,
Samir K. Gupta,
F. Post,
M. Bloch,
A. Avihingsanon,
G. Crofoot,
P. Benson,
K. Lichtenstein,
...
M. Ramgopal,
P. Chetchotisakd,
J. Custodio,
M. Abram,
Xuelian Wei,
A. Cheng,
S. McCallister,
Devi SenGupta,
M. Fordyce
|
7 |
2016 |
7
๐ข
|
|
๐
|
A Randomized, Double-Blind Comparison of Coformulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF vs Ritonavir-Boosted Atazanavir Plus Coformulated Emtricitabine and Tenofovir DF for Initial Treatment of HIV-1 Infection: Analysis of Week 96 Results
12 auth.
J. Rockstroh,
E. Dejesus,
K. Henry,
J. Molina,
J. Gathe,
S. Ramanathan,
...
Xuelian Wei,
Andrew Plummer,
M. Abram,
A. Cheng,
M. Fordyce,
J. Szwarcberg
|
6 |
2013 |
6
๐
|
|
๐
|
A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results.
11 auth.
N. Clumeck,
J. Molina,
K. Henry,
J. Gathe,
J. Rockstroh,
E. Dejesus,
...
Xuelian Wei,
K. White,
M. Fordyce,
M. Rhee,
J. Szwarcberg
|
6 |
2014 |
6
๐
|
|
๐ฌ
|
Anti-CD4 Monoclonal Antibody Ibalizumab Exhibits Breadth and Potency Against HIV-1, With Natural Resistance Mediated by the Loss of a V5 Glycan in Envelope
C. Pace,
M. Fordyce,
D. Franco,
Chia-Ying Kao,
M. Seaman,
D. Ho
|
6 |
2013 |
6
๐ฌ
|
|
๐
|
Cobicistat-boosted darunavir in HIV-1-infected adults: week 48 results of a Phase IIIb, open-label single-arm trial
12 auth.
K. Tashima,
G. Crofoot,
F. Tomaka,
T. Kakuda,
A. Brochot,
T. van de Casteele,
...
M. Opsomer,
W. Garner,
N. Margot,
J. Custodio,
M. Fordyce,
J. Szwarcberg
|
6 |
2014 |
6
๐
|
|
๐
|
Pharmacokinetics and Safety of Tenofovir Alafenamide in HIV-Uninfected Subjects with Severe Renal Impairment
7 auth.
J. Custodio,
M. Fordyce,
W. Garner,
M. Vimal,
K. H. Ling,
B. Kearney,
...
S. Ramanathan
|
5 |
2016 |
5
๐
|
